Edetic Acid

Edetic Acid

SCHEMBL818342

O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Pd+4]

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
ALOX15 P16050 2/20 0.68
MAPT P10636 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
TDP1 Q9NUW8 2/20 0.50
EYA2 O00167 1/20 0.50
APP P05067 1/20 0.50
ACE P12821 1/20 0.50
BLM P54132 2/20 0.48
PMP22 Q01453 2/20 0.48
LMNA P02545 1/20 0.48
CHRM2 P08172 1/20 0.48
ADRA2A P08913 1/20 0.48
TSHR P16473 1/20 0.48
DRD1 P21728 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
CYP2C19 P33261 1/20 0.48
ADRA1A P35348 1/20 0.48
DRD3 P35462 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edetic Acid SCHEMBL9131150 0.97 KDM4E (0.71) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL4530881 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL11090967 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL3100265 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL65335 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL14973164 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL11051608 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL11329382 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL355803 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1
Edetic Acid SCHEMBL144663 0.94 KDM4E (0.68) KDM4EALOX15MAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024258867-A1 SYSTEM AND METHOD FOR PRESERVING ALGAE Macro Oceans Inc. (US) 2024-12-19 WO disclosed
US-20240409878-A1 SYSTEM AND METHOD FOR PRESERVING ALGAE Macro Oceans Inc. (US) 2024-12-12 US disclosed
US-8507728-B2 Method for manufacturing ketone JX NIPPON OIL & ENERGY CORPORATION (JP) 2013-08-13 US disclosed
US-20110288340-A1 METHOD FOR MANUFACTURING KETONE JX NIPPON OIL & ENERGY CORPORATION (JP) 2011-11-24 US disclosed
EP-2364965-A1 KETONE MANUFACTURING METHOD JX Nippon Oil & Energy Corporation (JP) 2011-09-14 EP disclosed
US-20090127112-A1 Biologically active metal-coated proteins RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-05-21 US disclosed
WO-2006123343-A2 BIOLOGICALLY ACTIVE METAL-COATED PROTEINS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288340-A1 METHOD FOR MANUFACTURING KETONE CBR1, CBR3, ODC1 KDM4E 559/4885ALOX15 497/4885MAPT 3656/4885
US-20090127112-A1 Biologically active metal-coated proteins CUTA, S100B, CAB39 KDM4E 4703/4885ALOX15 4054/4885MAPT 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.